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VP1 is a capsid protein of foot-and-mouth disease virus (FMDV) and contains epitopes of the virus. Plasmids encoding two
VP1 epitopes (amino acid residues 141–160 and 200–213) and a host–self immunoglobulin molecule were constructed to
produce a new type of FMD DNA vaccine. Two plasmids, namely, pCEIM and pCEIS, containing mouse immunoglobulin (IgG)
or swine IgG were subjected to immunogenicity testing in mice and swine, respectively. In mice administrated pCEIM in the
abdomen using a genegun, both FMDV-specific T-cell proliferation and neutralizing antibodies were detected. In swine
immunized with pCEIS at the back of the ear, immune responses were achieved after the second administration. Swine
showed a T-cell proliferative response with a stimulation index (SI) of up to 8.1 and a neutralizing antibody response that was
able to protect suckling mice from 102 LD50 (lethal dose 50) FMDV challenge. To compare the immunogenicity of the
DNA-based vaccine candidate, versus the protein-based vaccine candidates, a second group of swine was immunized with
the protein F1-scIgG, which was encoded by the plasmid pCEIS. Injection with F1-scIgG elicited a T-cell proliferative
response of SI , 1.7 and a neutralizing antibody response that protected suckling mice from up to 105 LD50 FMDV challenge.
In the challenge test, three of three swine immunized with pCEIS were fully protected from FMDV challenge. © 2000 Academic
Press
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highly contagious viral disease of cloven-hoofed ani-
mals, such as pigs and cattle. FMD has the potential to
cause explosive epidemics and heavy economic losses
to the agricultural industry worldwide. In an FMD out-
break that occurred in Taiwan in 1997, the disease
spread from 3 farms in 2 prefectures to 5734 farms in 15
prefectures and 5 cities within 2 weeks, and ultimately
more than 300,000 swine had to be destroyed (http://
ss.niah.affrc.go.jp). FMD is caused by the foot-and-mouth
disease virus (FMDV), which belongs to the Aphthovirus
genus of the Picornaviridae family. The FMDV contains
one copy of single-strand RNA and 60 copies of each of
the four structural proteins (VP1–VP4). VP1 carries criti-
cal epitopes for inducing immune responses to FMDV (3,
6). Two major B-cell epitopes, VP1 (141–160) and VP1
(200–213), are able to induce neutralizing antibodies (3,
12, 31). VP1 (141–160) also contains at least one T-cell
epitope that is able to induce FMDV-specific T-cells (12,
31, 34).
A good vaccine should always have several essential
elements including safety and low cost in manufacture,
1 To whom correspondence should be addressed. Fax: (852) 2358-
559. E-mail: boyxie@ust.hk.
27storage, and administration (13). Vaccines currently used
against FMD are based on inactivated virus and have
been proven to be effective against the disease (1).
Chemically synthesized peptides or bacterially ex-
pressed proteins containing viral epitopes have also
been applied in the vaccine designations against FMDV.
However, there are problems associated with these
types of vaccines for which DNA vaccines provide an
ideal solution. Protein-based vaccines are heat-sensitive
and require low-temperature conditions during manufac-
turing and storage to maintain efficacy. Conventional
vaccines have raised safety concerns, as inactivated
virus vaccines have been found to be involved in out-
breaks of FMD caused by the release of incompletely
inactivated virus (21).
DNA vaccines provide a safe and efficient alternative.
The chemical nature of DNA contributes to the safety and
convenience in manufacturing, storage, and administra-
tion of DNA vaccines. Immunization with plasmid DNA is
able to elicit both cell-mediated and humoral immune
responses, a fact that has contributed much to its appeal
as a vaccine (9, 14, 29). The mechanism underlying each
DNA vaccine varies from case to case (33). DNA-en-
coded antigens can induce CD81 T-cells [(most cytotoxic
T-lymphocytes (CTL)] through the endogenous antigen
pathway. The plasmid mimics virus behavior and pro-
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28 RAPID COMMUNICATIONduces antigen inside the cell, leading to the formation of
peptide–MHC class I complexes (15). In the absence of
antibodies, CTL elicited by DNA immunization have been
proven to be able to provide protection against virus
infection (19, 35). DNA vaccination can also induce CD41
T-cells and neutralizing antibody; the secretory proteins
encoded by the plasmid and the antigen-presenting cells
(APCs) play an important role in this process (22, 33).
Viral epitopes have been found to be able to induce
immune responses but the responses are poor and
short-term (16). Large molecules such as hepatitis B
virus core antigen (11) or b-galactosidase (5) have been
linked to viral epitopes to improve the immunogenicity of
epitope vaccines. However, immunization with these for-
eign proteins is usually accompanied by a strong im-
mune response against irrelevant viral proteins and can
cause side effects with subsequent repeated immuniza-
tion. To avoid the risk of competing immunogenicity,
self-molecules such as MHC classes I and II have been
used as the carrier to deliver epitopes (4).
Our previous work has demonstrated that linking two
of the FMDV VP1 epitopes (amino acid residues 141–160
and 200–213) with the swine immunoglobulin (IgG) single
heavy chain constant region is able to elicit FMDV-spe-
cific immune responses in swine (8). The current study
aimed to develop a DNA vaccine candidate against FMD
by constructing plasmid encoding FMDV epitopes. The
variable region of host-self IgG single-chain cDNA was
replaced by synthesized nucleotides encoding the two
major FMDV epitopes VP1 (141–160) and VP1 (200–213)
TABLE 1
Determination of Neutralizing Antibody Response in Immunized
Micea Using Suckling Mice Protection Testb
Serumc pCEIM pCIM
Commercial
vaccine Blank
Protection (3 LD50M)
d 103 0 105 0
a Each group contained four mice. The mice in the first two groups
ere administered DNA plasmid in the abdomen with a genegun. Each
ouse received two bombardments and each cartridge contained 0.1
mg DNA. The positive control group was administered FMDV vaccine
and each mouse received 5 ml according to the manual. All mice
received a booster 4 weeks after the first administration and the sera
were collected 10 days after booster injection. The mice in the blank
group were given no treatment.
b 50 ml testing serum was inoculated into 2- to 3-day-old suckling
mice 24 h before inoculation of a 10-fold LD50 series of FMDV (e.g., 10
LD50, 10
2 LD50). Each FMDV challenge titer was tested in four suckling
ice and the highest titer that could be protected by the antisera in two
r more suckling mice ($2) in a group was recorded.
c Serum used was pooled serum collected from the four mice in a
group.
d LD50M is the half lethal dosage, determined as described under
aterials and Methods.to give rise to a self-molecule containing the viral
epitopes. The immune responses elicited by the plasmidwere investigated in mice and swine after administration
with a genegun. The difference in immunogenicity be-
tween DNA- and protein-based vaccine candidates in
swine was also investigated by comparing the different
immune responses elicited by administration of either
the plasmid or the protein encoded by the plasmid.
Results. Immunogenicity test in mice. T-cell prolifera-
tion and mice protection assays were carried out as
described under Materials and Methods. Blood samples
were collected from the four groups of mice 10 days after
the booster injection. Sera from mice immunized with the
commercial vaccine protected the suckling mice from a
105 LD50 (lethal dosage 50) FMDV challenge while the
blank group did not show any protection. Mice immu-
nized with pCEIM provided a protection level of 103 LD50,
hereas those immunized with pCIM did not show any
rotective effects (Table 1). For the T-cell proliferation
ssay, T-cells were incubated with 0.4, 2, 10, and 50
mg/ml purified viral protein. The cells incubated in less
than 10 mg/ml antigen showed no proliferation response
(data not shown). The mice immunized with pCEIM
showed a strong T-cell response to the stimulation of
viral protein and the highest stimulation index (SI)
reached 66 (Table 2).
Immunogenicity test in swine. Encouraged by the re-
sults in mice, further immunogenicity testing was carried
TABLE 2
T-Cell Response to Viral Protein Stimulation in Micea
after the Secondary Administration
Immunogen Mice
Lymphocyte proliferation
to antigenb (SI)c
10 mg/ml 50 mg/ml
pCEIM 1 7.2 37.1
2 10.1 28.9
3 12.7 18.0
4 21.6 66.6
pCIM 1 1.0 0.7
2 1.0 1.0
3 0.9 0.5
4 0.8 0.8
Commercial vaccine 1 1.3 1.5
2 1.5 1.4
3 1.2 2.1
4 0.9 0.8
Blank control 1 1.0 0.6
2 0.7 0.9
3 0.9 0.8
4 1.1 1.3
a Mice were grouped as described in footnote a of Table 1.
b T-cells were stimulated with 10 or 50 mg/ml purified viral protein.
The proliferation effect was determined by comparing the [3H]thymidine
aken up by the cells incubated with and without viral protein.
c SI (stimulation index) is the mean cpm of culture with antigen/mean
cpm of culture without antigen.
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29RAPID COMMUNICATIONout in swine. To investigate whether there were any
differences in the immuno-stimulatory effects of DNA
plasmid administered at various sites on the animal,
swine immunized with pCEIS were divided into two
groups; one was administered vaccine at the back of the
ear and the other on the inner side of the thigh. The
assays were carried out after both primary and second-
ary administrations to investigate the possible route of
plasmid immunization. None of the blood samples col-
lected after the primary administration from any of the
swine groups showed detectable immune responses. In
order to investigate the different immunogenicities of the
DNA-based versus the protein-based vaccine candi-
dates, another group of swine was immunized with the
protein F1-scIgG, which was encoded by the plasmid
pCEIS. Yet another group of swine was injected with the
commercial vaccine. After the secondary administration,
all swine immunized with the commercial vaccine and
T
Neutralizing Antibody Response in Immunized
Swine groups:
Administration at the ear
Swine: Swine 1 Swine 2
Administration: 1st 2nd 1st 2nd 1s
rotection (3 LD50M): 0 10
3 0 102 0
Swine groups:
pCIS
Swine: Swine 1 Swine 2
Administration: 1st 2nd 1st 2nd 1s
Protection (3 LD50M): 0 0 0 0 0
Swine groups:
Commercial vaccine
Swine: Swine 1 Swine 2
Administration: 1st 2nd 1st 2nd
Protection (3 LD50M): ND
b .105 c ND .105
a Each group contained three swine. The swine immunized with plas
wo bombardments of each cartridge containing 1 mg DNA. pCEIS was
with commercial vaccine and protein F1-sIgG were injected at the inner
interval. Sera were collected for testing 10 days after each administra
b ND, not determined.
c . means that the protection over the value shown here was not dF1-scIgG protein showed very strong neutralizing anti-
body responses with a titer that could give protection in
a
isuckling mice of more than 104 LD50M (LD50 in suckling
mice) of FMDV challenge (Table 3).
Swine receiving the pCEIM exhibited different anti-
body responses and T-cell proliferation when bom-
barded at different sites. Administration at the back of the
ear elicited protection ranging from 102 to 103 LD50 and
the T-cell response with SI ranged from SI 5.5 to 8.1. The
swine administered on the inner side of the thigh
showed a T-cell response ranging from SI 2.4 to 3.5 and
only one animal exhibited a neutralizing antibody re-
sponse (providing protection against doses of up to 10
LD50M). All swine in the blank group immunized with the
CEIM showed no neutralizing antibody production and
o T-cell response (Table 4).
Viral Challenge Test in Swine. Based on the results
escribed above, direct FMDV challenge tests on three
wine groups were carried out. The first group of chal-
enge swine were inoculated with pCEIS at the ear using
a Examined by Suckling Mice Protection Test
pCEIS
Administration at the thigh
3 Swine 1 Swine 2 Swine 3
2nd 1st 2nd 1st 2nd 1st 2nd
102 0 0 0 0 0 101
Negative control
Blank
3 Swine 1 Swine 2 Swine 3
2nd 1st 2nd 1st 2nd 1st 2nd
0 0 0 0 0 0 0
Positive control
F1-sIgG
ne 3 Swine 1 Swine 2 Swine 3
2nd 1st 2nd 1st 2nd 1st 2nd
.105 ND 105 ND 105 ND 104
CEIS or pCIS were bombarded with a genegun. Each animal received
red to the back of ear or the inner side of the thigh. Swine immunized
f the thigh. All immunized swine were inoculated twice within a 4-week
ine in the blank group were given no treatment.
ed.ABLE 3
Swine
Swine
t
Swine
t
Swi
1st
ND
mids p
delive
side o
tion. Swgenegun device. The second group of swine was
njected with a commercial vaccine as a positive control,
n cpm
30 RAPID COMMUNICATIONand the third blank group was tested as a negative
control. All three groups of swine were challenged with
10 LD50S (LD50 in swine) FMDV HK type O and co-housed
for 10 days. In the blank group, blisters appeared on the
feet and tongue in all experimental animals and their
body temperature increased to 41°C within 4 days.
Swine immunized with the commercial vaccine or pCEIS
exhibited no FMD symptoms during the 10-day observa-
tion period (Table 5).
Discussion. To our knowledge, this is the first report of
a DNA vaccine candidate encoding only FMDV epitopes
that can provide successful protection against direct
FMD viral challenge. In recent years, Mason and col-
leagues have developed several DNA vaccines against
FMDV (2, 10, 33). Among their designations, plasmid
pP12X3C, encoding the viral capsid (P1) gene and the
processing proteinase (3C), and another plasmid,
pWRMHX, encoding the entire FMDV genome with a
mutation at the cell-binding site, have been shown to
prevent the replicated genomes from causing disease.
Both plasmids were found to elicit detectable antiviral
immune responses while the replicating plasmid
pWRMHX produced a stronger response. In contrast to
the work mentioned above, our plasmid, pCEIS, encodes
only two major epitopes of FMDV (amino acid residues
141–160 and 200–213) instead of the whole genome or
T
T-Cell Response to Viral Protein Stimulation in
Immunogen Swine
Prim
10 mg/m
pCEIS at ear 1 1.3
2 1.5
3 1.6
pCEIS at thigh 1 1.1
2 1.0
3 0.9
pCIS at ear 1 1.3
2 0.8
3 0.7
F1-sIgG 1 NDc
2 ND
3 ND
Commercial vaccine 1 ND
2 ND
3 ND
Blank control (-ve) 1 1.0
2 1.1
3 0.8
a Swine were grouped as described in footnote a of Table 3.
b SI (stimulation index) is the mean cpm of culture with antigen/mea
c ND, not determined.intact proteins, and all three swine immunized with this
plasmid were protected against direct FMDV challenge.Epitopes by themselves are able to elicit an immune
response (3). FMDV epitope 141–160 was found to be
immunogenic when delivered in liposome form (16) or in
polymerized form. This carrier-independent activity is
due to the fact that the amino acid sequence contains
not only a B-cell epitope but also a T-cell epitope that can
elicit the T-helper response (6). However, peptides alone
are poorly immunogenic, and carriers are always added
to improve the immunogenicity of epitopes because of
their ability to provide the T-helper response (5). In our
study, in order to improve the immunogenicity of the
a after the First and Second Administrations
ministration Secondary administration
T cell proliferation to viral protein (SI)b
50 mg/ml 10 mg/ml 50 mg/ml
1.7 2.2 8.1
2.1 2.8 7.9
0.9 2.7 5.5
0.9 2.0 2.7
1.1 1.5 2.4
0.8 1.4 3.5
1.0 0.7 1.1
0.8 0.9 0.7
0.8 0.9 0.8
ND 1.3 1.6
ND 1.5 1.7
ND 1.5 1.6
ND 1.4 1.5
ND 2.0 1.7
ND 1.8 1.7
1.2 1.1 1.1
0.9 0.9 0.9
1.0 1.3 0.8
of culture without antigen.
TABLE 5
FMD Viral Challenge Testa in Swine
Swine groupb
No. of swine infectedc/
No. of swine challenged
pCEIS 0/3
Commercial vaccine 0/3
Blank 3/3
a All swine were challenged by injection of 1 ml of 10 LD50S/ml FMDV
at the neck region 10 days after the second administration.
b Each group had three swine and all swine were housed in sepa-
rated open-topped crates within one house.
c Swine were observed for 10 days after FMDV challenge. FMD
symptoms, such as an increase in body temperature (above 41°C) andABLE 4
Swine
ary ad
lthe appearance of blisters on the mouth or hooves, were detected in
infected swine.
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31RAPID COMMUNICATIONepitopes and simultaneously avoid epitopes causing ef-
fects and immune competition, a self IgG molecule was
chosen as the carrier for the epitopes. IgG has a long life
span in the host (9), and fusion with a IgG molecule can
extend the half-life of a short-lived molecule (7). There-
fore, self IgG carrier may overcome the problem of rapid
degradation of foreign epitopes and lead to a continuous
exposure to the host, thus enhancing the immunogenic-
ity of the epitopes in the host.
The suckling mice protection assay is a common
method in the FMDV study as an indicator of neutralizing
antibody contained in the adult mice serum and has
been found to have a good correlation with protection
(17, 23). Mulcahy et al. (24) compared the mouse protec-
tion test (MPT) and the standard plaque reduction test,
i.e., serum neutralizing test (SNT), in their study. The
results showed that the SNT was of less value in the
case of animals immunized with subunit vaccines and
very high SNT titers sometimes were seen in unpro-
tected animals. The results also showed that a .102.5
LD50M protection in suckling mice conferred successful
rotection against FMDV infection in bovine (24). In our
xperience, protection in swine immunized with protein-
ased vaccine requires a .103 LD50M protection in the
MPT. In our immunogenicity test in swine, the protection
antibody elicited by the plasmid was as low as 102
LD50M, which was approximately 1000-fold less than that
licited by the conventional inactivated virus vaccine.
his concentration was lower than that required for the
rotection against viral challenge in swine. Previous
tudies indicated that protection against FMDV is closely
ssociated with antibody reaction (13). Could there be
nother mechanism underlying the protection against
MDV in swine provided by the inoculation of plasmid
CEIS?
The cytotoxic T-cell response is a major immune re-
ponse against endogenous antigens, such as virus, in
he immune system (27, 36). Some studies indicated that
TL also play a role in the immune response to FMDV
nfection. Cattle immunized with a FMDV vaccine ex-
ressing the precursor polypeptide (P1) in a recombinant
denovirus vector exhibited protection against FMDV
nfection the absence of a detectable antibody response
28). In another study, the discovery and characterization
f a porcine CD81 T-cell clone with specificity for FMDV
provided direct evidence for the possibility of the pres-
ence of CTL during protection (26).
It has been suggested that FMDV vaccines with
proper designation of the antigen structure and presen-
tation pathway may lead to an effective CTL protective
immunity (25). Our vaccine candidate aimed to achieve
this goal through two designations: first, using a DNA
vaccine designation, and second, directing the antigen
encoded by the plasmid to undergo the endogenous
pathway after expression in the host cells. DNA vaccines
have a distinct advantage in comparison with the pro-
r
dtein-based vaccine, in that they are able to elicit CTL,
because the plasmid expresses the encoded proteins
inside the host cells and leads to a MHC class I-re-
stricted cell-mediated immunity (15). Plasmid DNA may
exert selective pressure and tend to elicit the T-helper
cell 1 response, therefore polarizing the immune re-
sponse to the cellular immunity (9).
Second, our designation was to induce CTL by direct-
ing the antigen encoded by the plasmid to undergo the
endogenous pathway after expression in the host cells.
The leading signal sequence was removed from the IgG
cDNA, and therefore the encoded epitope–IgG-constant
chain fusion protein lost its secretory ability and re-
mained inside the cell. Eventually, this molecule should
be processed through the MHC class I system and
consequently should lead to the activation of CD81 T
ells. In a study by Huang et al. (20), the researchers
onstructed two plasmids, namely, pCO1 and pBO1,
hich encoded FMDV epitopes and b-galactosidase,
dding an IgG signal peptide in order to produce a
ecretion protein. These two plasmids were tested on
uinea pigs by intramuscular (im) injection and no pro-
ection was observed although neutralizing antibodies
ere detected. This suggests that secretion proteins are
aken up into the cells by endocytosis or phagocytosis
nd undergo the exogenous pathway, and theoretically
his pathway could elicit humoral immune responses.
Our study demonstrated that administration of the
NA plasmids by the genegun device at different sites
n swine could induce various degrees of immune re-
ponsive effects. DNA plasmid bombardment at the back
f the ear elicited a strong response while bombardment
n the inner side of the thigh of the swine elicited a very
oor immune response, even though the thigh is the
traditional” injection site for protein-based vaccines. The
xplanation may be related to the mechanism of the
mmune response elicited by DNA vaccine and the phys-
ological property of the swine tissues. Muscle cells play
very important role in DNA immunization; however, the
xtensive connective tissue in the lap of swine may
nterfere with direct gene transfer into muscle cells (18).
n addition, the presence of abundant vascular tissues in
he ear may contribute to the efficient immunization of a
NA vaccine. Bombardment by a genegun can result in
irect transfection of DNA plasmids to APCs existing in
he blood vessels, such as macrophages and B-cells,
nd then being taken to distal tissue (30). Administration
f DNA vaccine at the thigh area by im injection may
roduce better results than using a genegun (31), be-
ause im injection can overcome the problem of ineffi-
ient transfection levels caused by the obstacle of tis-
ues.
In summary, this study clearly showed that using only
MDV epitopes in a DNA plasmid can elicit immuneesponses against FMDV and provide protection against
irect viral challenge. The different B- and T-cell re-
32 RAPID COMMUNICATIONsponses caused by plasmid pCEIS and protein F1-scIgG
demonstrated that DNA- and protein-based vaccines
may elicit immune responses through different mecha-
nisms. The higher T-cell response and lower antibody
response elicited by the plasmid and the protection
achieved against FMDV challenge indicated that the
inoculation of DNA plasmid may elicit a CTL response in
swine and play a role in the protection against FMD.
Materials and Methods. Virus culture, inactivation, and
viral protein purification. Serotype O15 HK type FMDV
was supplied by the Fishery and Agriculture Department
(Hong Kong SAR, China). BHK (clone 21) cells were a gift
from the Department of Biology, Hong Kong University
(Hong Kong SAR, China). FMDV was propagated in BHK
cells. The viral protein was purified as follows: BHK-21
cells were cultured in complete RPMI 1640 medium
(Gibco) until a monolayer of approximately 80% conflu-
ency was formed Then FMDV was added to infect the
cells for 45 min. The culture was collected for virus
protein purification after 75% of the cytopathogenic effect
of the BHK-21 cells had been reached. The virus was
inactivated in 0.01 M binaryethylenimine (Sigma) at 37°C
for 2 h and the viral protein purification was carried out
by ultra-centrifugation. The concentration of purified viral
protein was determined by measuring optical density at
259 nm and the protein was subjected to Western blot
analysis with anti-FMDV antibody for verification. Purified
viral protein was used in the T-cell proliferation assay as
an antigen.
Bacterial Expression of Protein F1-scIgG. Our previous
work included construction of a bacterially expressed
plasmid named pF1-scIgG (8). This plasmid uses pET16b
(Novagen) as its vector and encodes a protein named
F1-scIgG, within which F1 contains two FMDV epitopes
[VP1 (141–160) and VP1 (200–213)] and scIgG contains
the swine IgG heavy chain fragment. pF1-scIgG was
transformed into Escherichia coli BL21(DE3) pLysE and
the expression product, F1-scIgG, was purified with a
His-tagged affinity column.
Plasmid Engineering. The vector pcDNA3.1(1) (Invitro-
gen) is a stable mammalian expression vector containing
the markers of ampR for selection in bacterial cells and
a CMV promoter for expression in mammalian cells. As
shown in Fig. 1a, plasmids pCEIS and pCIS were con-
structed by substituting the pET-16b vector of pF1-scIgG
with vector pcDNA3.1. PCR was carried out with Vent
polymerase (NEB Biolab) and produced a F1-sIgG
fragment with EcoRI or XhoI restriction sites at each
end. The sequence of the sense and antisense prim-
ers was 59-ACGGAATTC(EcoRI)GTACCAAACCTG-39
and 59-ACGCTCGAG(XhoI)TCATTTACCCTG9, respec-
tively. The F1-sIgG fragment was cloned into the vector
of pcDNA3.1 between the EcoRI and the XhoI restric-
tion sites. Fragment sIgG was digested from pF1-scIgG between HindIII and XhoI restriction sites and
then subcloned into pcDNA3.1. As shown in Fig. 1b,
plasmids pCEIM and pCIM were constructed by sub-
stituting the swine IgG fragment with the mouse IgG
fragment in pCEIS or pCIS, respectively. The mouse
IgG heavy chain fragment was produced by RT-PCR.
Mouse IgG mRNA was purified from the spleen of a
Balb/c mouse with the FastPrep Kit (Gibco). Reverse
transcription was carried out with M-MuLV reverse
transcriptase at 37°C for 1 h. The primers used for
RT-PCR were designed based on the mouse IgG DNA
sequence found in GenBank (Accession No. L35037).
The sequence of the sense and antisense primers was
59-ACGAAGCTT(HindIII)GCAAAACGACACCC-39 and
59-ACGCTCGAG(XhoI)TTATTTACCAGGAGA9, respec-
tively. After construction, the plasmids pCEIS, pCIS,
pCEIM, and pCIM were subjected to restriction endo-
nuclease digestion mapping and sequencing.
Immunogenicity Test in Mice. Plasmid inoculation was
carried out using a Helios Gene Gun System (Bio-Rad).
Cartridges containing plasmid DNA (e.g., pCIM and
pCEIM) were prepared as described by the manufacturer
and pressure delivery at the abdomen of the mice was
300 psi. For each cartridge used for delivery in mice, 0.1
mg purified plasmid DNA was precipitated onto 0.5 mg of
1.6-mm gold particles and coated on the inner surface of
the tube in the presence of 0.5 mg/ml polyvinylpyrroli-
done (Sigma). Two groups of Balb/c mice (Animal Care
Center, Hong Kong University of Science and Technol-
ogy) were immunized with pCEIM or pCIM. Each group
containing four 4-week-old mice was immunized twice
within an interval of 4 weeks. Blood was collected for the
T-cell proliferation test and suckling mice protection test
10 days after the booster injection. Another group of mice
was injected with 5 ml of a commercially available con-
ventional FMDV vaccine (Aftopor, France), to serve as a
positive control, and yet another group of mice receiving
no treatment served as blank control.
Iummunogenicity Test in Swine. A cartridge containing
1.0 mg plasmid DNA (e.g., pCEIS and pCIS) was delivered
into swine by using a genegun device either at the back
of the ear or at the inner side of the thigh. The helium
pressure for delivery in swine was 600 psi. Each swine
received two bombardments. A total of 18 swine (provid-
ed by the Ming Tak Pig Farm of Hong Kong SAR, China),
each weighing 30–40 kg, were divided into six groups
(i.e., 3 in each group), and each group was subjected to
an immunogenicity test. The animals were kept in isola-
tion for a period of 2 weeks prior to experimentation and
were kept under controlled conditions during the exper-
iment. The swine were treated as follows: the first two
groups were administered plasmid pCEIS at the ear or
the thigh, respectively, the third group was administered
plasmid pCIS at both the ear and the thigh region, the
fourth group was injected with 0.5 mg F1-sIgG protein,
e
c
cIgG b
e IgG f
33RAPID COMMUNICATIONthe fifth group was injected with 1 ml commercial vac-
cine, which was a positive control, and the remaining
group was a blank group. Each swine was immunized
twice within an interval of 4 weeks. Blood samples were
collected for testing 10 days after each administration.
Mouse Protection Test. The LD50M of the stock O1K
FMDV was determined by injection of a 10-fold serial
dilution of the virus. The dilution concentration that
caused 50% of death of the suckling mice was the LD50.
After determination of LD50M, the suckling mice were
first inoculated with 50 ml of test serum obtained from
ither test mice or swine. Within 20–23 h the mice were
FIG. 1. (A) DNA plasmids pCEIS and pCIS were constructed by substi
out and produced a F1-sIgG fragment with EcoRI or XhoI restriction sites
and XhoI restriction sites. The fragment sIgG was digested from pF1-s
pCEIM and pCIM plasmids were constructed by substituting the swinhallenged with 10-fold LD50 FMDV. The suckling mice
were then observed for 4 days. If a suckling mousesurvived 24 h after the virus challenge, this indicated that
the serum sample was able to protect the mice from
such a dosage of virus challenge. Each FMDV challenge
titer was tested in four suckling mice and the highest titer
against which protection could be provided in more than
two mice in a group by the testing serum was recorded.
FMDV Challenge Test in Immunized Swine. The LD50S
of the stock O1K FMDV was determined by a method
similar to the determination of LD50M. Since FMDV is not
always lethal to swine, the observance of FMD symp-
toms was used as the indicator of infection instead of
death, as in the case of mice. Swine were monitored for
he pET-16b vector of pF1-scIgG with vector pcDNA3.1. PCR was carried
h end. The F1-sIgG fragment was cloned into pcDNA3.1 between EcoRI
etween HindIII and XhoI sites and then subcloned into pcDNA3.1. (B)
ragment with mouse IgG fragment in pCEIS or pCIS, respectively.tuting t
at eaca period of 10 days after FMDV challenge for the appear-
ance of FMD symptoms, such as an increase in body
g
i
34 RAPID COMMUNICATIONtemperature (above 41°C) and the appearance of blis-
ters on the mouth or hooves. After determination of
LD50S, a challenge test was carried out on three
roups of experimental swine (three per group) by
njection of 1 ml of 10 LD50S/ml FMDV at the neck
region 10 days after the second immunization. All
swine were kept in separated open-topped crates
within one house. After 10 days of observation, the
swine were destroyed and buried.
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